Virus Entry Inhibitors: Past, Present, and Future

Adv Exp Med Biol. 2022:1366:1-13. doi: 10.1007/978-981-16-8702-0_1.

Abstract

The approval of enfuvirtide marked a milestone for the development of virus entry inhibitor-based antiviral therapeutics. Since then, more peptide-, small-molecule-, and protein-based entry inhibitors have been identified and approved for viral diseases. Here we reviewed the development of virus entry inhibitors and the advantages and disadvantages of peptide-, small-molecule-, and protein-based entry inhibitors, herein summarizing the future trend of these antivirals. Virus entry inhibitors take effect outside the host cell, making them good candidates for development as pre- and post-exposure prophylaxis, microbicides, and therapeutics. This chapter, as well as this book, provides more information on the development and modification of peptide-, small-molecule-, and protein-based virus entry inhibitors.

Keywords: Entry inhibitor; Peptide; Small molecule; Therapeutics; Virus.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Enfuvirtide / pharmacology
  • HIV Fusion Inhibitors* / pharmacology
  • HIV Fusion Inhibitors* / therapeutic use
  • Peptides / pharmacology
  • Virus Internalization*

Substances

  • Antiviral Agents
  • HIV Fusion Inhibitors
  • Peptides
  • Enfuvirtide